Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.

Trial Details

NCT ID
NCT05929222
Phase
PHASE3
Sponsor
Fondazione Italiana Linfomi - ETS
Status
RECRUITING
Cancer Type
Follicular Lymphoma Lymphoma
Interventions
  • Radiotherapy
  • Radiotherapy plus Obinutuzumab
Locations (sample)
  • Sassuolo, Modena (MO), Italy|44.5432,10.7848
  • Alessandria, Italy|44.90924,8.61007
  • Avellino, Italy|40.91494,14.79103
  • Aviano, Italy|46.07056,12.59472
  • Bari, Italy|41.12066,16.86982

Key Eligibility Criteria

  • Histological documented diagnosis of Follicular Lymphoma grade I-IIIA as defined in the 2017 edition of World Health Organization (WHO)
  • Ann Arbor Stage IA or IIA (includible in one radiation field), or IE, non-bulky (\<7 cm). Stage must be determined by PET/CT scan (Appendix 2)
  • Patients performing PET before surgery can also be enrolled without repeating PET after surgery
  • No previous treatment except for steroid pre-treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Follicular Lymphoma Lymphoma Trials on Trialify →